Hair loss in women is meaningfully underreported and undertreated. Most of the clinical language around androgenetic alopecia — the Norwood Scale, DHT, finasteride — was developed in the context of male hair loss, and women's experience of the same underlying condition is both similar and importantly different. This article explains what androgenetic alopecia looks like in women, why it can look different than it does in men, how it is diagnosed, and which treatments may help.
The Basics: Same Mechanism, Different Pattern
Androgenetic alopecia in women, also called female pattern hair loss (female pattern hair loss), is driven by the same fundamental mechanism as in men. DHT and other androgens cause progressive miniaturization of genetically sensitive hair follicles. Over time, follicles produce progressively thinner, shorter, less pigmented hair.
The difference is in how the pattern presents. Women rarely develop the M-shaped frontal recession or the complete vertex baldness seen in advanced male androgenetic alopecia. Instead, female pattern hair loss presents as a diffuse reduction in hair density, most visible at the central part of the scalp. The frontal hairline is usually preserved (at least until later stages).
The Ludwig Scale is used to classify female pattern hair loss, analogous to the Norwood Scale for men:
Ludwig Type I: Perceptible thinning of the central part. Still covered by remaining hair.
Ludwig Type II: More pronounced widening of the central part. Scalp visible through the part.
Ludwig Type III: Diffuse thinning across the top of the scalp with severe reduction in density.
Female pattern hair loss produces central diffuse thinning rather than the hairline recession and vertex baldness seen in men. The frontal hairline is usually maintained, which is why it is often missed or misidentified.
The Role of Androgens in Women
Women produce testosterone and DHT, though at much lower levels than men. The ovaries and adrenal glands both contribute to female androgen production. After menopause, estrogen levels decline, which changes the androgen-to-estrogen ratio, increasing androgen activity relative to baseline.
This is why female pattern hair loss accelerates considerably after menopause in many women. The absolute androgen level may not change, but the relative influence of androgens increases as estrogen declines.
In women of reproductive age, elevated androgens — whether from polycystic ovarian syndrome (PCOS), congenital adrenal hyperplasia, or androgen-secreting tumors — can accelerate androgenetic alopecia meaningfully. In women who are not experiencing accelerated loss and who have no signs of androgen excess, androgen levels are often within the normal female range.
Not all women with androgenetic alopecia have elevated androgens. Many have normal androgen levels with genetic follicle sensitivity. Androgen excess as a cause is important to rule out but is not present in most women with female pattern hair loss.
Diagnosis: What to Evaluate
Diagnosing androgenetic alopecia in women involves ruling out other causes of hair loss and confirming the characteristic pattern.
Laboratory workup typically includes:
- Complete blood count: to screen for anemia
Serum ferritin: iron deficiency is common in premenopausal women and frequently co-contributes to hair loss
Thyroid function tests: hypothyroidism can cause diffuse shedding that mimics female pattern hair loss
Serum total and free testosterone: to screen for androgen excess
DHEA-S: another adrenal androgen marker
Sex hormone-binding globulin: affects free testosterone levels
Prolactin: hyperprolactinemia can contribute to hair loss
Vitamin D, zinc, and B12: common nutritional deficiencies that can amplify loss
This workup distinguishes androgenetic alopecia from other treatable causes of hair loss and identifies deficiencies that, when corrected, improve outcomes.
In women, the diagnostic workup for hair loss is broader than in men. Multiple nutritional and hormonal factors can mimic or co-contribute to the androgenic pattern, and identifying them changes the treatment approach. Treatment Options
The treatment range for women is narrower than for men, partly because many male hair loss treatments carry risks in women.
Minoxidil: The primary first-line topical treatment for women. FDA-approved at 2% (original approval) and 5% (subsequently approved). Both concentrations are effective. Studies show that 5% outperforms 2% in hair regrowth, though 2% with twice-daily application is also well-documented. Low-dose oral minoxidil at 0.625–1.25 mg daily is increasingly used in women and has shown meaningful results with a favorable tolerability profile at these doses.
Spironolactone: An aldosterone antagonist with anti-androgenic properties. Not FDA-approved for hair loss but widely used off-label in women at 50–200 mg daily. Multiple studies and substantial clinical experience support its efficacy in women with female pattern hair loss, particularly those with elevated androgens or hormone-sensitive patterns. Covered in detail in Article 24.
Finasteride and dutasteride: Not approved for use in women and contraindicated in women who are pregnant or may become pregnant due to the risk of birth defects. Post-menopausal women are sometimes prescribed finasteride or dutasteride off-label, with data suggesting modest benefit at low doses. These should only be used in women with confirmed contraception or post-menopausal status, under clinical supervision.
Low-level laser therapy: Safe for use in women. FDA-cleared devices produce meaningful improvement in hair density and are appropriate as an add-on.
Minoxidil is the primary evidence-based topical treatment for women. Spironolactone is widely used off-label with good supporting evidence. Finasteride and dutasteride call for careful patient selection and contraceptive counseling.
The Psychological Impact
The psychological burden of hair loss in women is consistently documented as significant and often underestimated by clinicians. A 2012 survey published in the Journal of Investigative Dermatology Symposium Proceedings found that women with hair loss reported meaningfully greater psychological distress than men with comparable hair loss severity. Body image concerns, reduced self-esteem, and social anxiety are common.
This context matters for treatment planning. The threshold for initiating treatment in women may appropriately be lower than a purely clinical assessment of loss severity would suggest, given the quality-of-life implications of even moderate loss.
Hair loss has a significant psychological impact in women that is often greater than in men with comparable severity. Early treatment and clear communication about realistic outcomes are important components of care. Summary
Androgenetic alopecia in women presents as central diffuse thinning rather than the patterned recession seen in men. It is driven by the same DHT-mediated miniaturization mechanism, but the clinical presentation, diagnostic approach, and treatment options differ meaningfully. The diagnostic workup should include nutritional and hormonal screening to identify co-contributors. Minoxidil is the primary first-line treatment. Spironolactone is widely used off-label with good evidence. Finasteride and dutasteride are options for carefully selected post-menopausal women. The psychological impact warrants proactive treatment even at earlier stages.